Antibody for immuno-oncology and ophthalmology
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
42
NCT06402201
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: May 24, 2024
Completion: Dec 31, 2027
Loading map...